T cell Targeting for Cancers and Autoimmune Diseases

Reference Sustained Effect Theory

FDA Grants Fast Track Designation for CTCL

A New Method to Induce Immunomodulation

Applications & Advantages

The therapy has potential application for T cell blood cancers, T cell driven autoimmune diseases, including multiple sclerosis, GI and other cancers. Resimmune® is also being investigated as an immunomodulator for therapy of metastatic melanoma. With the drug administered in four days versus multiple courses of other treatments, the drug has the potential to reduce both treatment time and expense. Resimmune® has been granted Orphan Drug Designation for the treatment of Cutaneous T-Cell Lymphoma (CTCL).

Licensing & Collaboration

Angimmune welcomes inquiries regarding licensing and collaboration with our technology. Our high potency DT390 Pichia platform can accept a wide variety of proprietary antibody sequences produced with Bivalent binding for increased affinity and internalization to targeted cells.